NeuroSense Therapeutics

Company Overview

Snapshot

Founded in February 2017 by Alon Ben-Noon, NeuroSense Therapeutics operates with 11–50 employees. The company has raised $24.2M across 7 funding rounds from 2 investors. In December 2021, NeuroSense Therapeutics completed its Initial Public Offering on the NASDAQ Capital Market.

Business overview

NeuroSense Therapeutics is a drug development company focused on creating treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Its core product, PrimeC, is a unique formulation combining two FDA-approved compounds. The company is currently conducting clinical trials for PrimeC in ALS patients in both Israel and the United States, serving the pharmaceutical and life sciences industries within the Health Tech & Life Sciences sector.

Strategic signal

In November 2025, NeuroSense Therapeutics received FDA clearance to initiate a pivotal Phase 3 trial for PrimeC in ALS. This regulatory approval is a significant validation of the drug's potential and marks a critical step towards commercialization, signaling strong progress in addressing a high-unmet medical need within the neurodegenerative disease market.

Company Intelligence Q&A

What was a significant recent regulatory milestone for NeuroSense Therapeutics?

In November 2025, NeuroSense Therapeutics received FDA clearance to initiate a pivotal Phase 3 trial for its lead drug candidate, PrimeC, for the treatment of ALS.

What recent financial activity did NeuroSense Therapeutics undertake?

In September 2025, NeuroSense Therapeutics announced a $500,000 private placement at a premium to its market price.

What patent was recently granted to NeuroSense Therapeutics?

In September 2024, NeuroSense Therapeutics was granted a key U.S. patent for its novel PrimeC formulation, which is its lead asset for ALS and Alzheimer's.

What are NeuroSense Therapeutics' plans for commercialization in Canada?

In October 2024, NeuroSense Therapeutics announced plans to file for early commercialization of its ALS treatment in Canada, with further updates provided in October 2024.

What was the outcome of NeuroSense Therapeutics' at-the-market equity offering program?

In October 2023, NeuroSense Therapeutics ended its at-the-market equity offering program, stating that the company is fully funded beyond its Clinical Phase 2b ALS results.